he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信息论地址
编辑: jiang上一页:初步发现急性风湿热死亡的预测因素
下一页:癫痫病要如何诊疗呢
- 2022-05-04朱砂的效用与作用 朱砂使用不当危害大
- 2022-04-28癫痫病症的症状有哪些呢
- 2022-04-13癫痫治疗障碍仍难以克服
- 2022-04-12抗癫痫药物预防新发癫痫:任重而道远
- 2022-04-11Clin cancer res:子宫内膜样卵巢癌或子宫内膜癌的治疗策略
- 2022-04-07在转移机制研究方面取得了重大进展
- 癫痫治疗障碍仍难以克服
- 抗癫痫药物预防新发癫痫:任重而道远
- FDA批准Aptiom用于治疗患者癫痫发作
- Clin cancer res:子宫内膜样卵巢癌或子宫内膜癌的治疗策略
- 在转移机制研究方面取得了重大进展
- 预测癫痫患者再入院风险
- 甲硝唑 VS 替硝唑,只是一字之差吗?
- 全球干细胞临床试验1000多项,在白癜风领域潜力巨大
- 在泰国,女性子宫实际上需要这些试管婴儿手术
- 世界妇科内部会议(ISGE)
- 治疗脑炎后遗症的方法有哪些?
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 特发性癫痫大发作药物治疗的首选
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 癫痫吃什么好?
- 溢液是怎么回事?
- 结核性宫颈炎有哪些症状?
- 儿童癫痫的早期症状 癫痫的原因
- 白癜风到底该怎么治疗?
- 癫痫的常见症状是什么?
- 癫痫病的最新治疗方法 癫痫发作的急救
- 脑膜炎球菌疫苗MenQuadfi欧盟批准
- 月经性癫痫患者妊娠期癫痫控制更好
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 心率多少正常 如何保持正常心率不变
- 癫痫会遗传吗 癫痫的治疗方法
- 综述:癫痫持续状态诊治最新进展
- 疗程癫痫病比较好的药物有哪些
- 治癫痫病哪里好敏感度好吗
- 治疗癫痫病小儿怎样治愈
- 造成小儿癫痫病的常见病因有什么
- 后期癫痫病症状表现是什么
- 痫病的治疗方法是什么 痫病有这些疗
- 于明治癫痫病能于明治的好么
- 癫痫病治疗哪家鳗鱼什么好呢
- Diabetologia:激活但功能受损的记忆Tregs在1型糖尿病病症进展缓慢的过程中逐渐扩展
- 癫痫病的疾病有哪些怎么治好
- 儿童癫痫病的发病副作用
- 20130712养生:杨红宣讲癫痫病人不能吃饱什么